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Kazutaka Nakayama,1 Ping Liu,2 Michelle Detry,6 Leslie R. Schover,3 Andrea Milbourne,4
Joyce Neumann,1 Gabriela Rondon,1 Belinda Thewes,7 Richard E. Champlin,1
Naoto T. Ueno1,5Hematopoietic stem-cell transplantation (HSCT) is associated with high rates of gonadal failure, which is dis-
tressing for younger patients desiring to start a family. The perceived importance and optimal timing of discus-
sing fertility- andmenopause-related informationwithwomen undergoing aggressive treatment such asHSCT
is not well defined. Questionnaires were sent to 532 patients who underwent HSCT between January 1987
and September 2004 at the ages of 16 to 50 years. The questionnaire assessed demographic data, the need
for fertility- andmenopause-related information at various times during treatment, and standardizedmeasures
of anxiety, qualityof life, andmenopausal symptoms. The return ratewas 40.2%,with 196patients participating.
Of these, 38% reported that they had discussed fertility-related issues with health-care providers since their
diagnosis; 54% had discussed menopause-related issues. At the time of diagnosis, participants considered re-
ceiving information on fertility and menopause as being of equal importance. However, after HSCT, informa-
tion about menopause was considered more important than information on fertility (P # .0001). Being\40
years, being childless, desiring to bear children in the future, and having a high score on the State-Trait Anxiety
Inventory (STAI) correlated with higher ratings of importance for both fertility- and menopause-related infor-
mation. Our results suggested that healthcare providers should provide information on fertility and meno-
pause repeatedly throughout the treatment period, and that menopause-related information should be
reemphasized after HSCT. Such counseling is crucial for patients who are young and childless.
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Advances in the technology associated with hema-
topoietic stem cell transplantation (HSCT) have
enabled its use for an increasing variety of diseases
[1-3]. As the number of long-term survivors after
HSCT increases, so too have reports of late side effects
in the physical, psychologic, and social realms [4].
These late effects of HSCT vary, and although most
are not life threatening, they nevertheless can signi-
ficantly affect the quality of life of long-term survi-
vors [5].
A particularly problematic late effect of HSCT is
the gonadal toxicity of the treatment [6]. Among pre-
menopausal women, the conditioning regimen often
results in premature ovarian failure (POF) with con-
comitant infertility, severe menopausal symptoms,
and sexual dysfunction [6-9]. Surveys have shown1465
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menopause are of considerable concern for many pa-
tients with cancer [10-12]. For patients of childbearing
age in particular, a loss of fertility was reported to be
almost as painful as was confronting the cancer itself
[10,12,13]. However, discussion of the fertility- and
menopause-related effects of treatment has not been
emphasized in the setting of HSCT, because the focus
of the oncology team is typically on eradicating disease
and extending patient survival.
Concern about fertility issues tends to be greater
among women who are young (#50 years) and child-
less [14,15]. Studies of young women with early-stage
breast cancer suggest that their informational needs
change over the course of cancer treatment [15-18].
Many patients considered getting fertility-related
information to be highly important at the time of the
treatment was being planned rather than at the end
of treatment [18]. In contrast, women were more
concerned about menopausal symptoms than about
fertility after treatment had ended. As methods of
preserving fertility for female cancer patients improve
[19], it will be even more important to describe the
available options for freezing gametes, embryos, or
ovarian tissue before cancer treatment is initiated
so that patients can decide whether to use these
modalities.
Although one survey indicated that HSCT patients
weremoreworried about dying than about their fertility
[20], a subsequent survey by Hammond and colleagues
[21] found that the prevalence of concerns over infertil-
ity was still higher among 10-year survivors of HSCT
than among control subjects. However, the optimal
type of information on reproductive issues (e.g., risks
of infertility versus dealingwithmenopausal symptoms)
and the optimal timing for delivery of that information
to women undergoing HSCT is not well defined. The
aims of this study were to assess patients’ perceptions
of the importance of receiving fertility- and meno-
pause-related information as a function of treatment
time—at diagnosis, during the cancer treatment before
HSCT, at the time of HSCT, and after HSCT. We
conducted our study by means of a questionnaire that
assessed demographic data, fertility- and menopause-
related information needs, and standardized measures
of anxiety and quality of life. To facilitate comparison
of our results with those of other studies, we modeled
our survey after that used by Thewes and colleagues
[18] in their retrospective qualitative study of patients
with early-stage breast cancer.MATERIALS AND METHODS
Patients and Procedures
This retrospective study was approved by the
institutional review board of The University of TexasM.D. Anderson Cancer Center. Potential participants
were identified by searching the database of the De-
partment of Stem Cell Transplantation and Cellular
Therapy at M. D. Anderson Cancer Center for female
patients who (1) had undergone HSCT between Janu-
ary 1987 and September 2004 at M. D. Anderson, (2)
had been 16 to 50 years old at the time of the
HSCT, (3) were living in the United States during
the study period, and (4) were alive at the time of the
survey. (Patients were assumed to be alive at the time
of survey if the record included mention of an outpa-
tient clinic visit or communication with healthcare
providers after February 2006.) Exclusion criteria
were a history of ovarian cancer or having had hyster-
ectomy or oophorectomy before HSCT. Question-
naires were sent to 532 eligible patients in September
2006. Questionnaire packets included a cover letter ex-
plaining the purpose of the study and elements of in-
formed consent. Patients were regarded as giving
implied consent to participate in this study if they
mailed a questionnaire that included some responses
to us. Patients who had not responded after 4 weeks
were telephoned to determine whether they intended
to participate. All responses received by the end of
February 2007 were included in the statistical analysis.Measures
The following data were extracted from patients’
charts: type of disease, age at diagnosis, age at
HSCT, treatment history before HSCT, type of con-
ditioning regimen, type of HSCT, gynecologic his-
tory, presence of chronic graft-versus-host disease
(cGVHD), and disease status (early versus advanced)
at HSCT, as defined previously [22].
The questionnaire we used in this study was based
on one created by Thewes et al [18,23] to assess the
need for fertility- and menopause-related information
among women with early-stage breast cancer. The
questionnaire consists of 3 parts. In the first part, par-
ticipants were asked for general information onmarital
status, parity, educational level, occupation, meno-
pausal status, and intention to have children. Section
2 included questions in the following domains. (A) Per-
ceived importance of fertility- and menopause-related infor-
mation. Participants were asked to rate their perception
of the importance of receiving fertility- and meno-
pause-related information at 3 time points: at the
time of diagnosis, at the time of HSCT, and at the
time of the survey. Answers were given on a 5-point
Likert scale ranging from 1 (not at all important) to 5
(extremely important). (B)Level of satisfaction with fertil-
ity- andmenopause-related information.Participantswere
asked to rate their satisfaction with the fertility- and
menopause-related information they received at the
same 3 time points (at diagnosis, at HSCT, and at sur-
vey). Answers were given on a 5-point Likert scale
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(C) Preferred timing of receiving fertility- and meno-
pause-related information. Participants were asked to
rate the importance of receiving fertility- and meno-
pause-related information at 4 different times during
the treatment continuum: at the time of diagnosis; dur-
ing the cancer treatment before HSCT, at the time of
HSCT, and after HSCT. Answers in this subsection
were given on a 6-point Likert scale ranging from
0 (not at all important) to 5 (extremely important).
The third section of this 3-part questionnaire consisted
of 3 brief test scales, all of which have demonstrated re-
liability and validity [18]. The first scale, the Spielberg
State-Trait Anxiety Inventory (STAI) Short Form, is
a brief 6-item measure of how anxious patients feel at
the moment (state anxiety) and how anxious they gen-
erally feel (trait anxiety) [24]. The second, the Greene
Climacteric Scale (GCS), is a 21-item menopausal-
symptom rating scale [25]. Participants were asked to
indicate the extent towhich they are currently bothered
by eachmenopausal symptom.Each symptom is scored
on 4-point scale ranging from 0 (not at all) to 3 (ex-
tremely). The third component of Section 3 of the
questionnaire was the Functional Assessment of Can-
cer Therapy–Bone Marrow Transplant (FACT-
BMT) [26], a 47-item questionnaire that includes
subscales on physical, social, emotional, and functional
well-being, as well as the patient’s relationship with her
doctor. Participants indicate the presence of symptoms
on a 5-point Likert scale ranging from 0 (not at all) to
4 (very much). Higher scores indicate a better quality
of life.Statistical Analysis
The demographic and clinical characteristics of the
entire patient population were analyzed with
descriptive statistics. For categoric variables, the
number of patients (frequency) was reported for each
value. The chi-square test, Fisher’s exact test, or
Fisher-Freeman-Halton test was used to evaluate
whether there was correlation between 2 categoric vari-
ables.Values ofP\.05 (two tailed) indicated significant
associations. For continuous variables, the following
summary statistics were presented: sample size, mean,
and standard deviation. The Spearman correlation co-
efficient was used to examine whether any 2 continuous
variables were correlated. The Wilcoxon test or the
Kruskal-Wallis test was used to compare the continu-
ous variables between and within groups.
Linear regression models were used to identify
important factors associated with the STAI, GCS,
and FACT-BMT scores. The following covariates
were included in the model: menstrual status, age at
HSCT, disease status at the time of the questionnaire,
and type of HSCT (autologous versus allogeneic,
myeloablative versus nonmyeloablative).RESULTS
Return Rate
Of the 566 women who met our eligibility criteria,
no contact information was available for 34, so 532
questionnaires were mailed to eligible patients.
Thirty-eight questionnaires (7%) were returned
because of unknown addresses, and 7 patients (1.3%)
were found to have died after the questionnaires
were mailed. One hundred ninety-six patients
responded, for a return rate of 40.2%.
Demographic and Clinical Characteristics
Table 1 summarizes demographic andmedical data
for the sample. The mean ages of the women at
diagnosis, at the time of the transplant, and at the
time of the survey were 36.3 years (range: 10-50 years),
38.4 years (range: 19-50 years), and 46.3 years (range:
23-66 years), respectively. The mean time since
HSCT was 7.9 years (range: 2.2-17.9 years). Approxi-
mately 70% of the women were married or living
with partners at the time of the transplant, and about
70% of the women had at least 1 child by the time of
the transplant. Seventy percent of the patients had
had hematologic cancers, and 25% had had solid
tumors. Fifty-four percent of the women had under-
gone autologous HSCT, and 39%, allogeneic
HSCT. A myeloablative regimen had been adminis-
tered to 84% of the patients.
To assess selection bias, we compared the patient
demographic data between those who responded to the
survey and those who did not. We found no differences
in demographic or medical characteristics (i.e., type of
disease, type of HSCT, type of conditioning regimen,
age at HSCT, and age at the time of the questionnaire)
between survey responders and nonresponders.
The Importance of Timing in Receipt of
Fertility- and Menopause-Related Information
The ratings for mean perceived importance of
receiving fertility- and menopause-related information
at 4 different times (at diagnosis, during the cancer treat-
ment before HSCT, at the time of HSCT, and after
HSCT) are shown in Figure 1. All mean values fell
within the upper half of the scale, suggesting that partic-
ipants believed that fertility- and menopause-related in-
formation was important at all time points.
Only for ‘‘at the time of diagnosis,’’ participants
rated fertility- and menopause-related information
were comparably important. At the all 3 subsequent
times, menopause-related information was rated as
more important than fertility-related information
(P5.03, P5.08, and P\ .0001). The importance of
information about fertility decreased after HSCT,
with significant differences between the times ‘‘during
cancer treatment before HSCT’’ and ‘‘after HSCT’’
Table 1. Demographic and Clinical Characteristics
of the Sample (N5196)
Characteristic Years N (%)
Current age
Mean 46.3
Range 23-66
Age at diagnosis
Mean 36.3
Range 10-50
Age at transplant
Mean 38.4
Range 19-50
Years from transplantation
Mean 7.9
Range 2.2-17.9
Disease
Aplastic anemia 2 (1.0)
Autoimmune disease 1 (0.5)
Hematologic Malignancy 138 (70.4)
Solid tumor 48 (24.5)
Data missing* 7 (3.6)
Type of HSCT
Autologous 105 (53.6)
Allogeneic 85 (39.3)
Autologous followed by allogeneic 5 (2.6)
Syngeneic 1 (0.5)
Data missing* 8 (4.1)
Type of conditioning regimen
Myeloablative 165 (84.2)
Reduced intensity 23 (11.7)
Data missing* 8 (4.1)
Marital status at the time of survey
Married 140 (71.4)
Living with a partner 6 (3.1)
Single 25 (12.8)
Divorced/separated 22 (11.2)
Widowed 3 (1.5)
Marital status at the time of HSCT
Married 135 (68.9)
Living with a partner 5 (2.6)
Single 39 (19.9)
Divorced/separated 17 (8.7)
Menstrual status at the time of survey
Cyclic menstruation 73 (37.2)
Irregular menstruation 16 (8.2)
Stopped before transplant 88 (44.9)
Stopped after transplant 14 (7.1)
Not sure/data missing 5 (2.6)
Number of children at the time of HSCT
0 58 (29.6)
1 35 (17.9)
>2 66 (33.7)
Number of children at the time of survey
0 52 (26.5)
1 34 (17.3)
2 69 (35.2)
>2 40 (20.4)
Data missing* 1 (0.5)
HSCT indicates hematopoietic stem cell transplantation.
*We failed to identify some patients because some returned question-
naires did not include patients’ name or identification numbers.
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ter HSCT’’ (P5.002) (Figure 1).
In contrast, the importance of menopause-related
information increased over the course of diagnosis,
treatment, and follow-up, with ratings for each of the
3 later time points significantly higher than that for
‘‘at the time of diagnosis’’ (P# .0001) and a significantincrease in importance from the time ‘‘during cancer
treatment before HSCT’’ to ‘‘after HSCT’’ (P5.01).
Factors Associated with the Perceived
Importance of Fertility-Related Information
Table 2 illustrates the relationship betweenmedical
and demographic characteristics and the perceptions of
the importance of fertility-related information. Factors
significantly associated with a higher rating of the im-
portance of fertility-related information included
younger age (being 40 years or younger at diagnosis
[P\ .0001], at HSCT [P\ .0001], and at the time of
the survey [P \ .0001]); single marital status at
HSCT (P5.009) and at the time of the survey
(P5.009); having ceased to menstruate at the time of
survey (P50.02); being childless (at HSCT [P \
.0001] and at the time of the survey [P50.0002]); and
wanting to have a child (at diagnosis [P\ .0001] and
at the time of the survey [P5.0008]). Women with
high STAI scores (i.e., with greater anxiety) rated fertil-
ity-related information as significantly more important
than did the other women in the study (P5.01).
Factors Affecting the Perceived Importance
of Menopause-Related Information
Table 3 shows the relationship between partici-
pants’ characteristics and the level of importance
they assigned menopause-related information.
Women aged 40 years or less (at diagnosis [P5.003],
at HSCT [P5.006], and at the time of the survey
[P5.0008]), childless women (at HSCT [P5.02]and
at the time of the survey [P5.046]), women wanting
a child (at diagnosis [P5.03] and at the time of the
survey [P5.02]), and women with high STAI scores
(i.e., with greater anxiety) rated menopause-related
information as significantly more important than did
the other women in the study (P5.02).
Satisfaction with the Fertility- and Menopause-
Related Information Received
Thirty-eight percent of the sample reported hav-
ing discussed fertility and 54% reported having dis-
cussed menopause-related issues with healthcare
providers since diagnosis. Younger women
(Figure 2A), childless women (Figure 2B), women
who wanted a child, women with lower FACT-BMT
scores (indicating poorer quality of life), and women
with higher GCS scores (i.e., with more bothersome
menopausal symptoms) were significantly more likely
to rate the fertility-related information they had been
given as less satisfactory at diagnosis, at the time of
HSCT, and at the time of the survey (Table 4).
Women who were single at the time of HSCT and at
the time of the survey were significantly more likely
to rate this information as less satisfactory, but only
at the time of the survey (Table 4).
22.5
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Figure 1. Importance of timing in receipt of fertility- andmenopause-related information for 196 patients. Mean values represent Likert scale: 05not at
all important; 55extremely important.
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quality of life) and with higher GCS scores (moremen-
opausal symptoms) were also significantly more likely
to rate menopause-related information as less satisfac-
tory at each time point. However, only being younger,
having no children, and desiring children at diagnosis
were significantly associated with dissatisfaction
with menopause-related information at the time of
the survey.DISCUSSION
Our results confirm that young women undergo-
ing HSCT need information about the impact of the
treatment on their fertility and about menopausal
symptoms regardless of their treatment time points.
Further, our results show that the perceived level of
importance of fertility- and menopause-related infor-
mation changes over the course of treatment and that
after HSCT, information on menopause may be
more important than information on fertility. These
results suggest that healthcare providers should offer
information about infertility and menopause repeat-
edly over the course of treatment. In particular, meno-
pause-related information should be reemphasized
after HSCT. Our findings further show that the per-
ceived importance of getting information on fertility
or menopause issues was associated with the severity
of menopausal symptoms and the quality of life.
Women with high anxiety levels and poor quality of
life tended to express greater needs for fertility- and
menopause-related information and to not be satisfied
with the information they received.
Although some studies have addressed psychoso-
cial or quality-of-life issues among patients who
undergo HSCT [27,28], as far as we know, this is the
first study focusing on changes in the need for informa-
tion on fertility and on menopause over the course oftreatment and on the link between patients’ quality
of life and their need for information on these topics.
When similar studies were conducted with patients
who were treated for less advanced cancer, their infor-
mation needs also varied over time but were always
considered important [16-18]. In an Australian study
of young women with early-stage breast cancer, the
retrospectively rated importance of both menopause-
and fertility-related information tended to increase
during the treatment period, although fertility was
consideredmore important during diagnosis and treat-
ment planning, whereas menopausal symptoms were
more troublesome after treatment was finished [18].
In our study, we used essentially the same methodol-
ogy as did the Australian study, and found similar
results, except that the perceived importance of fertil-
ity-related information declined over time. This
decline may reflect the very high rate of POF after
HSCT, which may necessitate a greater acceptance
of infertility over time for those who survive the
HSCT. Notably, even though the prognosis for
patients undergoing HSCT is generally considered
worse than that for patients undergoing other less risky
forms of treatment, the patients still wanted informa-
tion on fertility. Our results thus indicate that health-
care providers cannot assume that someone with
a poor prognosis has given up on the desire to have
children. Indeed, the mean ratings of the importance
of fertility-related information all stayed in the upper
half of the scale over time. Thus, it is reasonable to as-
sume that fertility issues are still important even after
HSCT. However, because options for restoring fertil-
ity after HSCT are very limited [6], fertility-related
information should be emphasized before HSCT as
much as possible.
Menopausal issues, on the other hand, tend to take
on more importance after HSCT, particularly because
POF is quite common (if not generally unavoidable)
after HSCT. Thus, healthcare providers should
Table 2. Importance of Fertility-Related Information at the Time of HSCT
Variables Mean (N)* SD Spearman r P value†
Age at the time of survey 20.425 <.0001
Age when cancer was diagnosed 20.41 <.0001
Age at HSCT 20.412 <.0001
Years since HSCT 20.049 .52
FACT-BMT score 20.078 .3
GCS score 0.005 .95
STAI score 20.189 .01
Hysterectomy
No 3.19 (132) 2.07 .08
Yes 2.45 (42) 2.35
Chronic GVHD
No 3.03 (148) 2.16 .85
Yes 2.96 (27) 2.17
Disease status at HSCT
Advanced 3.21 (94) 2.08 .22
Early 2.74 (77) 2.26
Disease status at the time of survey
Complete response 2.88 (101) 2.19 .47
Others 3.35 (20) 2.13
Diagnosis
Aplastic anemia 3.00 (2) 0 .21
Autoimmune disease 5.00 (1) —
Hematologic malignancy 3.17 (131) 2.11
Solid tumor 2.45 (42) 2.3
Myeloablative regimen
No 2.38 (21) 2.31 .14
Yes 3.11 (154) 2.13
Type of HSCT
Autologous 2.94 (99) 2.17 .5
Allogeneic (sibling donor) 3.10 (52) 2.07
Allogeneic (unrelated donor) 3.43 (21) 2.27
Marital status at HSCT
Single 4.00 (38) 1.63 .009
Living with a partner 2.50 (4) 2.89
Married 2.73 (123) 2.21
Divorced/separated 2.71 (17) 2.31
Marital status at the time of survey
Single 3.75 (24) 1.7 .009
Living with a partner 5.00 (5) 0
Married 2.89 (129) 2.21
Divorced/separated 2.67 (21) 2.27
Widowed 0 (3) 0
Menstrual status
No menstrual activity 4.12 (25) 1.33 .02
Menstrual activity 2.80 (156) 2.24
Number of children at HSCT
No child 4.04 (56) 1.63 <.0001
More than 1 child 2.53 (126) 2.24
Number of children at the time of survey
No child 3.94 (51) 1.68 .0002
More than 1 child 2.63 (131) 2.24
Childbearing plan at diagnosis
No plan for children 2.43 (119) 2.24 <.0001
Plan or have children 4.05 (63) 1.59
Childbearing plan the time of survey
No plan for children 2.74 (151) 2.24 .0008
Plan or have children 4.28 (29) 1.19
HSCT indicates hematopoietic stem-cell transplantation; GVHD, graft-versus-host disease.
*Patients rated importance on a 5-point Likert scale (15not at all important; 55extremely important).
†P-values are from Wilcoxon test or Kruskal-Wallis test.
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times during treatment planning and delivery and espe-
cially afterHSCT.Counseling on how to cope with an-
noying menopausal symptoms may be particularly
valuable not only for women who have severe meno-
pausal symptoms but also for those experiencing poor
quality of life in other areas.Our study confirms others’ findings that younger
age, being childless, and desiring more children all
tend to increase women’s distress about infertility
and menopausal symptoms [21]. We further found
that disease-specific variables such as disease status,
type of HSCT, and the presence of cGVHD did not
correlate with the perceived importance of
Table 3. Importance of Menopause-Related Information at the Time of HSCT
Variable Mean (N)* SD Spearman r P value†
Age at the time of survey 20.243 .0008
Age when cancer was diagnosed 20.219 .003
Age at HSCT 20.205 .006
Years from HSCT 20.111 .14
FACT-BMT score 20.125 .09
.17
GCS score 0.102 0
STAI score 20.17 .02
Hysterectomy
No 3.45 (135) 1.79 .52
Yes 3.13 (45) 2.1
Chronic GVHD
No 3.29 (154) 1.89 .07
Yes 3.89 (27) 1.72
Disease status at HSCT
Advanced 3.67 (96) 1.69 .047
Early 3.02 (81) 2.04
Disease status at the time of survey
Complete response 3.27 (104) 1.95 .39
Others 3.81 (21) 1.57
Diagnosis
Aplastic anemia 2.50 (2) 0.71 .37
Autoimmune disease 5.00 (1) —
Hematologic malignancy 3.45 (132) 1.86
Solid tumor 3.13 (47) 1.98
Myeloablative regimen
No 3.50 (22) 1.99 .57
Yes 3.36 (159) 1.86
Type of HSCT
Autologous 3.27 (103) 1.88 .28
Allogeneic (sibling donor) 3.49 (53) 1.91
Allogeneic (unrelated donor) 3.82 (22) 1.62
Marital status at HSCT
Single 3.71 (38) 1.64 .39
Living with a partner 3.25 (4) 2.36
Married 3.21 (128) 1.93
Divorced/separated 3.71 (17) 1.9
Marital status at the time of survey
Single 3.54 (24) 1.69 .17
Living with a partner 4.40 (5) 1.34
Married 3.34 (133) 1.91
Divorced/separated 3.36 (22) 1.89
Widowed 1.00 (3) 1.73
Menstrual status
No menstrual activity 3.68 (25) 1.49 .47
Menstrual activity 3.30 (161) 1.94
Number of children at HSCT
No child 3.89 (55) 1.46 .02
More than 1 child 3.14 (132) 2
Number of children at the time of survey
No child 3.82 (51) 1.49 .046
More than 1 child 3.19 (136) 1.99
Childbearing plan at diagnosis
No plan for children 3.15 (123) 1.96 .03
Plan or have children 3.77 (64) 1.65
Childbearing plan at the time of survey
No plan for children 3.23 (155) 1.93 .02
Plan or have children 4.07 (29) 1.41
HSCT indicates hematopoietic stem-cell transplantation; GVHD, graft-versus-host disease; GCS, Greene Climacteric Scale; FACT-BMT, Functional
Assessment of Cancer Therapy–Bone Marrow Transplant; STAI, State-Trait Anxiety Inventory.
*Patients rated importance on a 5-point Likert scale (15not at all important; 55extremely important).
†P-values are from Wilcoxon test or Kruskal-Wallis test.
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consistent with that of a previous report by Hammond
and colleagues [21]. It is well known that HSCT can
reduce quality of life in a variety of ways [29]. Women
who reported a poorer general quality of life and more
menopausal symptomswere alsomore dissatisfied withthe information they had received on both fertility and
menopause from their healthcare providers. Unfortu-
nately, the retrospective nature of our survey prevents
our knowing whether this association means that
women with more severe symptoms have a greater
need for help or whether reporting more symptoms
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Figure 2. Patients’ satisfaction with the fertility- and menopause-related information that had been provided. (A) Comparison between patients aged
40 years or older (N5100) (upper) and those younger than 40 years (N596) (lower) at the time of HSCT. (B) Comparison between patients with chil-
dren (N5101) (upper) and those without children (N558) (lower) at the time of HSCT.
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part of a bias to respond negatively. This is a limitation
of our study. A prospective study could help to untan-
gle these relationships.
Another limitation of our study was the somewhat
modest return rate (40.2%). This rate is not necessarily
low for written surveys that include questions on sensi-
tive topics such as fertility [30]. Although we found no
significant differences in demographic and clinical char-
acteristics between responders and nonresponders to the
questionnaire, it is possible that responders were more
concerned about fertility or menopause symptoms.
Conversely, the opposite might be true—that women
for whom fertility was very importantmight not have re-
sponded because it was too painful to revisit the topic.
Thus, this low return ratemight reflect a higher than an-ticipated level of concern about fertility and menopause
amongpatientswhochosenot toparticipate in this study.
In 2006, the American Society of Clinical Oncology
recommended that oncologists discuss fertility preser-
vation with all patients at the earliest possible opportu-
nity [19]. Nevertheless, only 30%–60% of patients with
cancer report having discussed infertility and earlymen-
opause with healthcare providers [14]. In our study,
only 38% and 54% of patients reported that they had
received infertility- and menopause-related informa-
tion, respectively, since diagnosis. At M.D. Anderson,
written information related to infertility and POF has
been routinely provided since the 1990s to all premen-
opausal or perimenopausal female patients before
HSCT. However, patients who underwent HSCT be-
fore 1990may not have been given specific information.
Table 4. Correlation of Patient Variables with Their Satis-
faction with Fertility-Related Information at Different Time
Points
Variable
When Cancer
Was
Diagnosed
(P-Value)
At the
Time
of HSCT
(P-Value)
At the
Time
of Survey
(P-Value)
Age at the time of survey .008 .003 .0004
Age when cancer was diagnosed .01 .004 .0008
Age at HSCT .001 .0004 <.0001
Years since HSCT .58 .80 .84
FACT-BMT score .004 .001 <.0001
GCS score .01 .001 .002
STAI score .37 .18 .054
Hysterectomy .06 .09 .006
Chronic GVHD .06 .12 .94
Disease status at HSCT .13 .15 .49
Disease status at time of survey .19 .33 .24
Diagnosis .39 .73 .69
Myeloablative regimen .99 .61 .79
Type of HSCT .27 .11 .26
Marital status at HSCT .43 .16 .0003
Marital status at the time of
survey
.40 .30 .01
Menstrual status .26 .20 .17
Number of children at HSCT .002 .0004 <.0001
Number of children at the time
of survey
.02 .002 <.0001
Childbearing plan at diagnosis .0004 <.0001 <.0001
Childbearing plan at the
time of survey
.01 .02 .0006
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-
versus-host disease; NS, not significant; GCS, Greene Climacteric Scale;
FACT-BMT, Functional Assessment of Cancer Therapy–Bone Marrow
Transplant; STAI, State-Trait Anxiety Inventory.
Biol Blood Marrow Transplant 15:1465-1474, 2009 1473Fertility and Menopause Issues in Women Undergoing HSCTIt is also possible that long-term survivors no longer re-
call information provided years before.
We do not yet know the best format for effective
provision of information, but our findings suggested
that patients be given information about the risks of in-
fertility and menopause-related issues more than once
during the course of treatment planning, delivery, and
follow-up, and perhaps that discussions of fertility be
emphasized before HSCT and discussions of meno-
pause emphasized after HSCT. Although these con-
clusions may seem intuitive, they have not been
addressed to date. Our findings should encourage on-
cology teammembers to begin discussing reproductive
health issues with women from the time of diagnosis
through long-term survivorship.ACKNOWLEDGMENTS
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